Subacute Cutaneous Lupus Erythematosus clinical trials

Explore recruiting subacute cutaneous lupus erythematosus clinical trials.

Recruiting subacute cutaneous lupus erythematosus studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Subacute Cutaneous Lupus Erythematosus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Multiple Ascending Doses of BMS-986326 in Participants with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus

Netherlands, Poland, Romania, Germany, Spain, Bulgaria

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Multicenter, Randomized, Double‑blind, Placebo‑controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Antimalarial Therapy

Bulgaria, Denmark, Spain, Poland, Netherlands, Greece +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants with Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

France, Poland, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A 2-Part Seamless Part A (Phase 2)/ Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

Bulgaria, Poland, Sweden, Italy, Spain, Hungary +5 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lupus Erythematosus (Subacute Cutaneous Lupus Erythematosus and/or Discoid Lupus Erythematosus) Participants Receiving Standard of Care

Spain, Greece, Romania, Poland, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants with Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations.

Greece, Spain, Poland, Germany, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

Subacute Cutaneous Lupus Erythematosus trials by city

Subacute Cutaneous Lupus Erythematosus clinical trials

Recruiting subacute cutaneous lupus erythematosus studies right now

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

Also recruiting in Europe

Multiple Ascending Doses of BMS-986326 in Participants with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus

A Multicenter, Randomized, Double‑blind, Placebo‑controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Antimalarial Therapy

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants with Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants with Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations.

Subacute Cutaneous Lupus Erythematosus trials by city

Other conditions